RxDoctor Payments Data

Wandaly I Pardo-Ruiz, MD

Hematology & Oncology · Hato Rey, PRNPI 1154525566

Payments from drug & device makers

$1,137in general payments, 2019–2025

Across 37 payments — averaging $30.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$292
  • Sanofi$141
  • Novocure Inc.$133
  • Takeda Pharmaceuticals U.S.A., Inc.$54
  • AbbVie$53
  • Genentech USA, Inc.$46
  • plus $417 from 17 others

What the payments were for

  • Food & beverage$1,137100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,137 in reported general payments places this provider in the 15th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$1,301,080
Medicare patients
289
Services billed
81,828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib23$355,094
PomalystPomalidomide12$283,523
TagrissoOsimertinib Mesylate18$278,103
IbrancePalbociclib13$195,305
LibtayoCemiplimab-Rwlc19$185,670
BrukinsaZanubrutinib12$169,400
Lenalidomide12$136,827
TecentriqAtezolizumab11$110,861
Lupron DepotLeuprolide Acetate18$102,895
EliquisApixaban104$70,221
Azacitidine17$60,658
Abiraterone Acetate24$49,646
MvasiBevacizumab-Awwb14$45,911
ZirabevBevacizumab-Bvzr12$37,542
ProcritEpoetin Alfa31$34,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis, Zirabev$20$303,068129 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$292$283,52312 claims
AstraZenecaTagrisso$15$278,10318 claims
AbbVieLupron Depot$53$102,89518 claims
Johnson & JohnsonProcrit, Xarelto$44$57,21453 claims
AmgenMvasi$36$45,91114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in Hato Rey

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →